MA50159A - Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps - Google Patents

Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps

Info

Publication number
MA50159A
MA50159A MA050159A MA50159A MA50159A MA 50159 A MA50159 A MA 50159A MA 050159 A MA050159 A MA 050159A MA 50159 A MA50159 A MA 50159A MA 50159 A MA50159 A MA 50159A
Authority
MA
Morocco
Prior art keywords
antibodies
frames
new stable
variable areas
stable combinations
Prior art date
Application number
MA050159A
Other languages
English (en)
Inventor
Dania Diem
Christian Hess
Sebastian Meyer
David Urech
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA50159A publication Critical patent/MA50159A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050159A 2017-09-20 2018-09-19 Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps MA50159A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17192206.5A EP3459968A1 (fr) 2017-09-20 2017-09-20 Nouvelles combinaisons de structure de domaines variables d'anticorps stables

Publications (1)

Publication Number Publication Date
MA50159A true MA50159A (fr) 2020-07-29

Family

ID=59982265

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050159A MA50159A (fr) 2017-09-20 2018-09-19 Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps

Country Status (8)

Country Link
US (2) US11421035B2 (fr)
EP (2) EP3459968A1 (fr)
JP (2) JP2020535799A (fr)
CN (1) CN111133000A (fr)
AU (1) AU2018335823B2 (fr)
CA (1) CA3073882A1 (fr)
MA (1) MA50159A (fr)
WO (1) WO2019057787A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL243311B (en) * 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
EP3816185A1 (fr) 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP3915580A1 (fr) 2020-05-29 2021-12-01 Numab Therapeutics AG Anticorps multi-spécifique
EP3988568A1 (fr) 2020-10-21 2022-04-27 Numab Therapeutics AG Traitement combiné
WO2022136693A1 (fr) 2020-12-23 2022-06-30 Numab Therapeutics AG Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
KR20230123981A (ko) 2020-12-23 2023-08-24 누맙 세러퓨틱스 아게 Il-4r에 결합하는 항체 가변 도메인
EP4019090A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps liant il-4r
EP4019546A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Domaines variables d'anticorps qui se lient à il-31
EP4019547A1 (fr) 2020-12-23 2022-06-29 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour il-4r et il-31
JP2024504471A (ja) 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
WO2022171771A1 (fr) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Protéines de liaison à l'antigène c3 du complément
EP4183800A1 (fr) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Nouveaux anticorps neutralisants du sars-cov-2
CR20240265A (es) 2021-12-22 2024-10-16 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
AU2023265474A1 (en) 2022-05-06 2024-10-31 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4273162A1 (fr) 2022-05-06 2023-11-08 Numab Therapeutics AG Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
WO2024038095A1 (fr) 2022-08-16 2024-02-22 Iome Bio Nouveaux anticorps anti-rgmb
AU2024275787A1 (en) 2023-05-19 2025-11-27 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2025133389A1 (fr) 2023-12-22 2025-06-26 Numab Therapeutics AG Domaines de liaison à un anticorps ayant une spécificité pour lilrb2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP1958962A3 (fr) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Polypeptides anticorps artificiels
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
HUE034269T2 (en) * 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
WO2008004834A1 (fr) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
US8193235B2 (en) 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
WO2014030780A1 (fr) * 2012-08-22 2014-02-27 Mogam Biotechnology Research Institute Procédé de criblage et de fabrication de domaines variables d'immunoglobulines super-stables et applications associées
IL243311B (en) * 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
EP3060579A1 (fr) * 2013-10-25 2016-08-31 Numab AG Constructions bispécifiques et leur utilisation dans le traitement de diverses maladies
IL293435B1 (en) 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format

Also Published As

Publication number Publication date
JP2020535799A (ja) 2020-12-10
EP3684802A1 (fr) 2020-07-29
WO2019057787A1 (fr) 2019-03-28
US11421035B2 (en) 2022-08-23
AU2018335823A1 (en) 2020-02-27
US20200255533A1 (en) 2020-08-13
CN111133000A (zh) 2020-05-08
AU2018335823B2 (en) 2025-09-04
EP3459968A1 (fr) 2019-03-27
US20230242651A1 (en) 2023-08-03
JP2023115024A (ja) 2023-08-18
CA3073882A1 (fr) 2019-03-28

Similar Documents

Publication Publication Date Title
MA50159A (fr) Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps
MA49043A (fr) Formulation stable d'anticorps
EP3811971A4 (fr) Anticorps permettant de bloquer l'interaction cd47-sirpa et application associée
EP3784707A4 (fr) Compositions de microcapsules de polyurée stables
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3478249A4 (fr) Compositions de microcapsules stables
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
EP3615079C0 (fr) Formulations de cannabinoïdes stables
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
MA54052A (fr) Formulation d'anticorps
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3419599A4 (fr) Formulations d'antagonistes d'il-6 et leurs utilisations
EP3692072A4 (fr) Anticorps anti-hla-dq2.5
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
EP3938077A4 (fr) Analyseur de concentration de point d'intervention
EP3773721A4 (fr) Formulations d'immunoconjugué anti-cd79b stables
EP3621640A4 (fr) Constructions d'anticorps d'acide nucléique optimisées
EP3893931A4 (fr) Méthodes d'utilisation d'anticorps anti-trem2
EP3849527C0 (fr) Formulations de composés de cyclosérine et leurs applications
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA54139A (fr) Formulation d'anticorps
EP3849612A4 (fr) Variants d'anticorps anti-vih 10-1074